AAAAAA

   
Results: 1-21 |
Results: 21
DIFFERENTIAL QUANTITATIVE EFFECTS OF INTERLEUKIN (IL)-2 AND IL-15 ON CYTOTOXIC ACTIVITY AND PROLIFERATION BY LYMPHOCYTES FROM PATIENTS RECEIVING IN-VIVO IL-2 - THERAPY
Authors: DEJONG JLO FARNER NL JAVORSKY BR LINDSTROM MJ HANK JA SONDEL PM
Citation: Jlo. Dejong et al., DIFFERENTIAL QUANTITATIVE EFFECTS OF INTERLEUKIN (IL)-2 AND IL-15 ON CYTOTOXIC ACTIVITY AND PROLIFERATION BY LYMPHOCYTES FROM PATIENTS RECEIVING IN-VIVO IL-2 - THERAPY, Clinical cancer research, 4(5), 1998, pp. 1287-1296
DIFFERENTIAL QUANTITATIVE EFFECTS OF INTERLEUKIN (IL)-2 AND IL-15 ON CYTOTOXIC ACTIVITY AND PROLIFERATION BY LYMPHOCYTES FROM PATIENTS RECEIVING IN-VIVO IL-2 - THERAPY
Authors: DEJONG JLO FARNER NL JAVORSKY BR LINDSTROM MJ HANK JA SONDEL PM
Citation: Jlo. Dejong et al., DIFFERENTIAL QUANTITATIVE EFFECTS OF INTERLEUKIN (IL)-2 AND IL-15 ON CYTOTOXIC ACTIVITY AND PROLIFERATION BY LYMPHOCYTES FROM PATIENTS RECEIVING IN-VIVO IL-2 - THERAPY, Clinical cancer research, 4(5), 1998, pp. 1287-1296
TRANSCRIPTION FACTOR ACTIVATION IN LYMPHOKINE-ACTIVATED KILLER-CELLS AND LYMPHOCYTES FROM PATIENTS RECEIVING IL-2 IMMUNOTHERAPY
Authors: NICOLET CM SURFUS JM HANK JA SONDEL PM
Citation: Cm. Nicolet et al., TRANSCRIPTION FACTOR ACTIVATION IN LYMPHOKINE-ACTIVATED KILLER-CELLS AND LYMPHOCYTES FROM PATIENTS RECEIVING IL-2 IMMUNOTHERAPY, Cancer immunology and immunotherapy, 46(6), 1998, pp. 327-337
COMBINATION THERAPY WITH INTERLEUKIN-2 AND ANTITUMOR MONOCLONAL-ANTIBODIES
Authors: SONDEL PM HANK JA
Citation: Pm. Sondel et Ja. Hank, COMBINATION THERAPY WITH INTERLEUKIN-2 AND ANTITUMOR MONOCLONAL-ANTIBODIES, The cancer journal from Scientific American, 3, 1997, pp. 121-127
PHASE IB TRIAL OF CHIMERIC ANTIDISIALOGANGLIOSIDE ANTIBODY PLUS INTERLEUKIN-2 FOR MELANOMA PATIENTS
Authors: ALBERTINI MR HANK JA SCHILLER JH KHORSAND M BORCHERT AA GAN J BECHHOFER R STORER B REISFELD RA SONDEL PM
Citation: Mr. Albertini et al., PHASE IB TRIAL OF CHIMERIC ANTIDISIALOGANGLIOSIDE ANTIBODY PLUS INTERLEUKIN-2 FOR MELANOMA PATIENTS, Clinical cancer research, 3(8), 1997, pp. 1277-1288
A PHASE I IB TRIAL OF MURINE MONOCLONAL ANTI-GD2 ANTIBODY 14.G2A PLUSINTERLEUKIN-2 IN CHILDREN WITH REFRACTORY NEUROBLASTOMA - A REPORT OFTHE CHILDRENS CANCER GROUP/
Authors: FROST JD HANK JA REAMAN GH FRIERDICH S SEEGER RC GAN J ANDERSON PM ETTINGER LJ CAIRO MS BLAZAR BR KRAILO MD MATTHAY KK REISFELD RA SONDEL PM
Citation: Jd. Frost et al., A PHASE I IB TRIAL OF MURINE MONOCLONAL ANTI-GD2 ANTIBODY 14.G2A PLUSINTERLEUKIN-2 IN CHILDREN WITH REFRACTORY NEUROBLASTOMA - A REPORT OFTHE CHILDRENS CANCER GROUP/, Cancer, 80(2), 1997, pp. 317-333
CLINICAL AND IMMUNOLOGICAL EFFECTS OF GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR COADMINISTERED WITH INTERLEUKIN-2 - A PHASE IB STUDY
Authors: SCHILLER JH HANK JA KHORSAND M STORER B BORCHERT A HUSEBYMOORE K BURNS D WESLY O ALBERTINI MR WILDING G SONDEL PM
Citation: Jh. Schiller et al., CLINICAL AND IMMUNOLOGICAL EFFECTS OF GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR COADMINISTERED WITH INTERLEUKIN-2 - A PHASE IB STUDY, Clinical cancer research, 2(2), 1996, pp. 319-330
ACTIVATION OF HUMAN EFFECTOR-CELLS BY A TUMOR REACTIVE RECOMBINANT ANTIGANGLIOSIDE GD(2) INTERLEUKIN-2 FUSION PROTEIN (CH14.18-IL2)
Authors: HANK JA SURFUS JE GAN JC JAEGER P GILLIES SD REISFELD RA SONDEL PM
Citation: Ja. Hank et al., ACTIVATION OF HUMAN EFFECTOR-CELLS BY A TUMOR REACTIVE RECOMBINANT ANTIGANGLIOSIDE GD(2) INTERLEUKIN-2 FUSION PROTEIN (CH14.18-IL2), Clinical cancer research, 2(12), 1996, pp. 1951-1959
SYSTEMIC INTERLEUKIN-2 MODULATES THE ANTIIDIOTYPIC RESPONSE TO CHIMERIC ANTI-GD2 ANTIBODY IN PATIENTS WITH MELANOMA
Authors: ALBERTINI MR GAN J JAEGER P HANK JA STORER B SCHELL K RIVEST T SURFUS J REISFELD RA SCHILLER JH SONDEL PM
Citation: Mr. Albertini et al., SYSTEMIC INTERLEUKIN-2 MODULATES THE ANTIIDIOTYPIC RESPONSE TO CHIMERIC ANTI-GD2 ANTIBODY IN PATIENTS WITH MELANOMA, Journal of immunotherapy with emphasis on tumor immunology, 19(4), 1996, pp. 278-295
ANTI-RENAL-CELL CARCINOMA CHIMERIC ANTIBODY G250 FACILITATES ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY WITH IN-VITRO AND IN-VIVO INTERLEUKIN-2-ACTIVATED EFFECTORS
Authors: SURFUS JE HANK JA OOSTERWIJK E WELT S LINDSTROM MJ ALBERTINI MR SCHILLER JH SONDEL PM
Citation: Je. Surfus et al., ANTI-RENAL-CELL CARCINOMA CHIMERIC ANTIBODY G250 FACILITATES ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY WITH IN-VITRO AND IN-VIVO INTERLEUKIN-2-ACTIVATED EFFECTORS, Journal of immunotherapy with emphasis on tumor immunology, 19(3), 1996, pp. 184-191
LYSIS OF HUMAN TUMOR-CELL LINES BY CANINE COMPLEMENT PLUS MONOCLONAL ANTIGANGLIOSIDE ANTIBODIES OR NATURAL CANINE XENOANTIBODIES
Authors: HELFAND SC HANK JA GAN J SONDEL PM
Citation: Sc. Helfand et al., LYSIS OF HUMAN TUMOR-CELL LINES BY CANINE COMPLEMENT PLUS MONOCLONAL ANTIGANGLIOSIDE ANTIBODIES OR NATURAL CANINE XENOANTIBODIES, Cellular immunology, 167(1), 1996, pp. 99-107
CLINICAL AND IMMUNOLOGICAL EFFECTS OF TREATMENT WITH MURINE ANTI-CD3 MONOCLONAL-ANTIBODY ALONG WITH INTERLEUKIN-2 IN PATIENTS WITH CANCER
Authors: HANK JA ALBERTINI M WESLY OH SCHILLER JH BORCHERT A MOORE K BECHHOFER R STORER B GAN J GAMBACORTI C SOSMAN J SONDEL PM
Citation: Ja. Hank et al., CLINICAL AND IMMUNOLOGICAL EFFECTS OF TREATMENT WITH MURINE ANTI-CD3 MONOCLONAL-ANTIBODY ALONG WITH INTERLEUKIN-2 IN PATIENTS WITH CANCER, Clinical cancer research, 1(5), 1995, pp. 481-491
A PHASE-II TRIAL OF HUMAN RECOMBINANT INTERLEUKIN-2 ADMINISTERED AS A4-DAY CONTINUOUS-INFUSION FOR CHILDREN WITH REFRACTORY NEUROBLASTOMA,NON-HODGKINS-LYMPHOMA, SARCOMA, RENAL-CELL CARCINOMA, AND MALIGNANT-MELANOMA - A CHILDRENS CANCER GROUP STUDY
Authors: BAUER M REAMAN GH HANK JA CAIRO MS ANDERSON P BLAZAR BR FRIERDICH S SONDEL PM
Citation: M. Bauer et al., A PHASE-II TRIAL OF HUMAN RECOMBINANT INTERLEUKIN-2 ADMINISTERED AS A4-DAY CONTINUOUS-INFUSION FOR CHILDREN WITH REFRACTORY NEUROBLASTOMA,NON-HODGKINS-LYMPHOMA, SARCOMA, RENAL-CELL CARCINOMA, AND MALIGNANT-MELANOMA - A CHILDRENS CANCER GROUP STUDY, Cancer, 75(12), 1995, pp. 2959-2965
FUNCTIONAL INTERLEUKIN-2 RECEPTORS ARE EXPRESSED ON NATURAL KILLER-LIKE LEUKEMIC-CELLS FROM A DOG WITH CUTANEOUS LYMPHOMA
Authors: HELFAND SC MODIANO JF MOORE PF SOERGEL SA MACWILLIAMS PS DUBIELZIG RD HANK JA GELFAND EW SONDEL PM
Citation: Sc. Helfand et al., FUNCTIONAL INTERLEUKIN-2 RECEPTORS ARE EXPRESSED ON NATURAL KILLER-LIKE LEUKEMIC-CELLS FROM A DOG WITH CUTANEOUS LYMPHOMA, Blood, 86(2), 1995, pp. 636-645
POTENTIAL TO INVOLVE MULTIPLE EFFECTOR-CELLS WITH HUMAN RECOMBINANT INTERLEUKIN-2 AND ANTIGANGLIOSIDE MONOCLONAL-ANTIBODIES IN A CANINE MALIGNANT-MELANOMA IMMUNOTHERAPY MODEL
Authors: HELFAND SC SOERGEL SA DONNER RL GAN J HANK JA LINDSTROM MJ SONDEL PM
Citation: Sc. Helfand et al., POTENTIAL TO INVOLVE MULTIPLE EFFECTOR-CELLS WITH HUMAN RECOMBINANT INTERLEUKIN-2 AND ANTIGANGLIOSIDE MONOCLONAL-ANTIBODIES IN A CANINE MALIGNANT-MELANOMA IMMUNOTHERAPY MODEL, Journal of immunotherapy with emphasis on tumor immunology, 16(3), 1994, pp. 188-197
TREATMENT OF NEUROBLASTOMA PATIENTS WITH ANTIGANGLIOSIDE GD(2) ANTIBODY PLUS INTERLEUKIN-2 INDUCES ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITYAGAINST NEUROBLASTOMA DETECTED IN-VITRO
Authors: HANK JA SURFUS J GAN J CHEW TL HONG R TANS K REISFELD R SEEGER RC REYNOLDS CP BAUER M WIERSMA S HAMMOND D SONDEL PM
Citation: Ja. Hank et al., TREATMENT OF NEUROBLASTOMA PATIENTS WITH ANTIGANGLIOSIDE GD(2) ANTIBODY PLUS INTERLEUKIN-2 INDUCES ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITYAGAINST NEUROBLASTOMA DETECTED IN-VITRO, Journal of immunotherapy with emphasis on tumor immunology, 15(1), 1994, pp. 29-37
INDUCTION OF LYMPHOKINE-ACTIVATED KILLER ACTIVITY IN CANINE LYMPHOCYTES WITH LOW HUMAN RECOMBINANT INTERLEUKIN-2 IN-VITRO
Authors: HELFAND SC SOERGEL SA MODIANO JF HANK JA SONDEL PM
Citation: Sc. Helfand et al., INDUCTION OF LYMPHOKINE-ACTIVATED KILLER ACTIVITY IN CANINE LYMPHOCYTES WITH LOW HUMAN RECOMBINANT INTERLEUKIN-2 IN-VITRO, Cancer biotherapy, 9(3), 1994, pp. 237-244
CLINICAL AND IMMUNOLOGICAL EFFECTS OF HUMAN RECOMBINANT INTERLEUKIN-2GIVEN BY REPETITIVE WEEKLY INFUSION TO NORMAL DOGS
Authors: HELFAND SC SOERGEL SA MACWILLIAMS PS HANK JA SONDEL PM
Citation: Sc. Helfand et al., CLINICAL AND IMMUNOLOGICAL EFFECTS OF HUMAN RECOMBINANT INTERLEUKIN-2GIVEN BY REPETITIVE WEEKLY INFUSION TO NORMAL DOGS, Cancer immunology and immunotherapy, 39(2), 1994, pp. 84-92
ALLOGENEIC T-CELL CLONES ABLE TO SELECTIVELY DESTROY PHILADELPHIA CHROMOSOME-BEARING (PH(1-) CELLS FROM THE SAME PATIENT()) HUMAN LEUKEMIA LINES CAN ALSO RECOGNIZE PH(1)
Authors: OETTEL KR WESLY OH ALBERTINI MR HANK JA ILIOPOLIS O SOSMAN JA VOELKERDING K WU SQ CLARK SS SONDEL PM
Citation: Kr. Oettel et al., ALLOGENEIC T-CELL CLONES ABLE TO SELECTIVELY DESTROY PHILADELPHIA CHROMOSOME-BEARING (PH(1-) CELLS FROM THE SAME PATIENT()) HUMAN LEUKEMIA LINES CAN ALSO RECOGNIZE PH(1), Blood, 83(11), 1994, pp. 3390-3402
ACTIVATION OF MULTIPLE EFFECTOR MECHANISMS TO ENHANCE TUMOR-IMMUNOTHERAPY
Authors: HANK JA ALBERTINI MR SCHILLER J SONDEL PM
Citation: Ja. Hank et al., ACTIVATION OF MULTIPLE EFFECTOR MECHANISMS TO ENHANCE TUMOR-IMMUNOTHERAPY, Journal of immunotherapy with emphasis on tumor immunology, 14(4), 1993, pp. 329-335
MODULATION OF TARGET-CELL CULTURE CONDITIONS ALTERS SUSCEPTIBILITY TOLYMPHOCYTE-MEDIATED LYSIS
Authors: ALBERTINI MR HOWARD SP FISCH P LINDSTROM MJ HANK JA GOULD MN SONDEL PM
Citation: Mr. Albertini et al., MODULATION OF TARGET-CELL CULTURE CONDITIONS ALTERS SUSCEPTIBILITY TOLYMPHOCYTE-MEDIATED LYSIS, Journal of immunotherapy with emphasis on tumor immunology, 13(4), 1993, pp. 243-251
Risultati: 1-21 |